RAINFALLs On Lilly's Cyramza Stomach Cancer Parade
A lack of overall survival benefit in first-line stomach cancer in a Phase III trial has scuppered Eli Lilly's hopes of expanding Cyramza's use into a new and relatively empty market.
A lack of overall survival benefit in first-line stomach cancer in a Phase III trial has scuppered Eli Lilly's hopes of expanding Cyramza's use into a new and relatively empty market.